New York State Common Retirement Fund
IKT icon

New York State Common Retirement Fund’s Inhibikase Therapeutics IKT Stock Holding History

New York State Common Retirement Fund’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$97.2K Hold
47,900
– – ﹤0.01% 2708
2026
Q1 		$80.5K Hold
47,900
– – ﹤0.01% 2619
2025
Q4 		$98.2K Hold
47,900
– – ﹤0.01% 2611
2025
Q3 		$77.6K Sell
47,900
-12,800
-21% -$22.2K ﹤0.01% 2770
2025
Q2 		$118K Buy
+60,700
New +$119K ﹤0.01% 2481

Other funds holding IKT

AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
AHL
Abel Hall LLC Baton Rouge, Louisiana $579M AUM 54.21% 1-Year Est. Return
TCA
Transcend Capital Advisors Madison, New Jersey $1.48B AUM 25.55% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

New York State Common Retirement Fund's IKT Position: Q2 2026 in Review

New York State Common Retirement Fund held its Inhibikase Therapeutics (IKT) position steady in Q2 2026 at 47,900 shares worth $97.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2708.

New York State Common Retirement Fund first reported a position in IKT in Q2 2025 and has held it in 5 quarters since. The position peaked at $118K in Q2 2025. 13 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • New York State Common Retirement Fund held 47,900 shares of Inhibikase Therapeutics worth $97.2K as of Q2 2026.
  • New York State Common Retirement Fund left its Inhibikase Therapeutics share count unchanged in Q2 2026.
  • Inhibikase Therapeutics made up ﹤0.01% of New York State Common Retirement Fund's portfolio in Q2 2026, its #2708 holding.
  • New York State Common Retirement Fund first reported a position in Inhibikase Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • New York State Common Retirement Fund's Inhibikase Therapeutics position peaked at $118K in Q2 2025.
  • 13 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on New York State Common Retirement Fund's 13F filing for Q2 2026, filed 29 Jul 2026.